US equities
|
GOOGL
$286.55
▼-11.80%
GOOG
$284.63
▼-11.57%
MSFT
$527.03
▼-0.75%
MU
$953.37
▼-3.04%
AMZN
$245.61
▼-3.53%
NVDA
$213.40
▼-0.92%
META
$624.07
▲+1.89%
LITE
$936.64
▲+2.48%
GOOGL
$286.55
▼-11.80%
GOOG
$284.63
▼-11.57%
MSFT
$527.03
▼-0.75%
MU
$953.37
▼-3.04%
AMZN
$245.61
▼-3.53%
NVDA
$213.40
▼-0.92%
META
$624.07
▲+1.89%
LITE
$936.64
▲+2.48%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Guardant Health, Inc. - Common Stock
(NQ:
GH
)
185.42
+2.83 (+1.55%)
Delayed Quote
Updated: 10:03 AM EDT, Oct 29, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Guardant Health, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
Guardant Health Applauds New Law Ensuring Access to Colorectal Cancer Screening Innovations with No Cost-Sharing for Pennsylvanians
Today 8:05 EDT
From
Guardant Health, Inc.
Via
Business Wire
3 Reasons GH is risky and 1 stock to buy instead
October 26, 2026
What a fantastic six months it’s been for Guardant Health. Shares of the company have skyrocketed 93.5%, hitting $171.24. This was partly due to its solid qu...
Via
StockStory
Topics
Bankruptcy
Supply Chain
Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026
October 20, 2026
From
Guardant Health, Inc.
Via
Business Wire
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning
↗
October 19, 2026
AI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound.
Via
MarketBeat
Topics
Artificial Intelligence
Guardant Health (NASDAQ:GH) Shares Surge After Q2 Revenue Beat and Raised 2026 Outlook
↗
July 30, 2026
Via
Chartmill
Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests
October 15, 2026
From
Guardant Health, Inc.
Via
Business Wire
3 of Wall Street’s Favorite Stocks That Fall Short
October 15, 2026
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...
Via
StockStory
Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer
October 08, 2026
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026
October 08, 2026
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma
October 05, 2026
From
Guardant Health, Inc.
Via
Business Wire
3 Cash-Burning Stocks with Questionable Fundamentals
October 05, 2026
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses...
Via
StockStory
Topics
Bankruptcy
Supply Chain
1 Mid-Cap Stock for Long-Term Investors and 2 We Ignore
September 29, 2026
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe...
Via
StockStory
1 Unpopular Stock That Should Get More Attention and 2 We Question
September 21, 2026
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...
Via
StockStory
Topics
Credit Cards
Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH)
September 15, 2026
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Guardant Health (NASDAQ:GH) a...
Via
StockStory
Guardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening
September 14, 2026
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer
September 09, 2026
From
Guardant Health, Inc.
Via
Business Wire
Business Insider Names Guardant Health One of America's Most Innovative Businesses
September 08, 2026
From
Guardant Health, Inc.
Via
Business Wire
1 Growth Stock to Add to Your Roster and 2 We Turn Down
September 08, 2026
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr...
Via
StockStory
Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer
September 04, 2026
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening
September 01, 2026
From
Guardant Health, Inc.
Via
Business Wire
Why Rule Breakers Buy a Stock That's Already "Won"
↗
August 31, 2026
You found a great company, then watched it double before you got round to buying.
Via
The Motley Fool
Topics
Death
Guardant Health to Appeal Federal District Court Judgment
August 24, 2026
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Sees Shield, MRD and Oncology Testing Growth Accelerate
↗
August 14, 2026
Guardant Health (NASDAQ:GH) highlighted growth across its oncology testing, minimal residual disease, and colorectal cancer screening businesses at the Canaccord Genuity Growth Conference, with co-CEOs...
Via
MarketBeat
Executive Dumps Over 14,000 Shares of Biotech Stock, Valued at $2.3 Million
↗
August 12, 2026
Ian Clark exercised stock options at $50.57 and immediately liquidated the position as the precision oncology company trades near $160 per share.
Via
The Motley Fool
Topics
Regulatory Compliance
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 10, 2026
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health (GH) Q2 2026 Earnings Call Transcript
↗
August 07, 2026
Shield screening volumes more than doubled, with UnitedHealth coverage now active.
Via
The Motley Fool
Topics
Earnings
2 Cash-Burning Stocks to Target This Week and 1 We Find Risky
August 03, 2026
While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sh...
Via
StockStory
Topics
Energy
GH Q2 Deep Dive: Shield Coverage and Oncology Uptake Drive Strong Revenue Growth
August 01, 2026
Diagnostics company Guardant Health (NASDAQ:GH) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 44.3% year on year to $33...
Via
StockStory
Guardant Health Q2 Earnings Call Highlights
↗
July 31, 2026
Guardant Health (NASDAQ:GH) reported second-quarter 2026 revenue of $335 million, up 44% from a year earlier, as growth accelerated across its oncology, biopharma and data, and screening businesses....
Via
MarketBeat
Topics
Earnings
Guardant Health (NASDAQ:GH) Delivers Strong Q2 CY2026 Numbers, Stock Soars
July 30, 2026
Diagnostics company Guardant Health (NASDAQ:GH) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 44.3% year on year to $3...
Via
StockStory
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
